Abstract
Inhibition of microbial protein synthesis is one of the most commonly used and important mechanisms of action for antibiotics. In addition to the four larger antibiotic classes (aminoglycosides, tetracyclines, oxazolidinones and macrolides) that operate by this mechanism, several smaller antibiotic classes also employ it. This review covers key members and important developments in the lincosaminide, streptogramin, phenicol, pleuromutilin, fusidane, pseudomonic acid, and thiopeptide classes of fermentation-derived antibiotics. Retapamulin is the most recently approved antibiotic from this group while some other members of these seven classes are currently in the antibiotic development pipeline. In addition, many other smaller classes of previously discovered antibiotics remain under-explored and under-utilized, which, if further examined, could represent additional opportunities and starting materials for creating new scaffolds for novel antibiotics.
Keywords
- Fusidic Acid
- Semisynthetic Derivative
- Peptidyl Transferase Center
- Bacterial Protein Synthesis
- Microbial Protein Synthesis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Agrawal RK, Heagle AB, Frank J (2000) Studies of elongation factor G-dependent tRNA translocation by three-dimensional cryo-electron microscopy. In: Garrett RA, Douthwaite SR, Liljas A, Matheson AT, Moore PB, Noller HF (eds) The ribosome: structure, function, antibiotics, and cellular interactions. ASM Press, Washington DC
Anderson B, Hodgkin DC, Viswamitra MA (1970) The structure of thiostrepton. Nature 225:233–235
Anstead GM, Owens AD (2004) Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 17:549–555
Arndt H-D, Schoof S, Lu J-Y (2009) Thiopeptide antibiotic biosynthesis. Angew Chem Int Ed 48:6770–6773
Bacque E, Barriere J-C, Berthaud N (2005) Recent progress in the field of antibacterial pristinamycins. Curr Med Chem Anti-Infect Agents 4:185–217
Bagley MC, Dale JW, Merritt EA, Xiong X (2005) Thiopeptide antibiotics. Chem Rev 105:685–714
Bartlett JG (2008) Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 46(Suppl 1): S4–S11
Baumann S, School S, Harkal SD, Arndt H-D (2008) Mapping the binding site of thiopeptide antibiotics by proximity-induced covalent capture. J Am Chem Soc 130:5664–5666
Blanchard SC, Cooperman BS, Wilson DN (2010) Probing translation with small-molecule inhibitors. Chem Biol 17:633–645
Bøsling J, Poulsen SM, Vester B, Long KS (2003) Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein L3. Antimicrob Agents Chemother 47:2892–2896
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12
Bower J, Drysdale M, Hebdon R, Jordan A, Lentzen G, Matassova N, Murchie A, Powles J, Roughley S (2003) Structure-based design of agents targeting the bacterial ribosome. Bioorg Med Chem Lett 13:2455–2458
Bush K, Pucci MJ (2011) New antimicrobial agents on the horizon. Biochem Pharmacol 82:1528–1539
Bush K et al (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9:894–896
Butler MS, Cooper MA (2011) Antibiotics in the clinical pipeline in 2011. J Antibiot 64:413–425
Canu A, Leclercq R (2001) Overcoming bacterial resistance by dual target inhibition: the case of streptogramins. Curr Drug Targets Infect Disord 1:215–225
Cempra Pharmaceuticals (2011) Fusidic acid dosing regimens for treatment of bacterial infections. WO/2011/008193
Cempra Pharmaceuticals (2012) http://www.cempra.com
Chain EB, Mellows G (1977) Pseudomonic acid. Part 1. The structure of pseudomonic acid A, a novel metabolite produced by Pseudomonas fluorescens. J Chem Soc Perkin Trans I 1977:294–309
Charney J, Fisher WP, Curran C, Machlowitz RA, Tytell TA (1953) Streptogramin, a new antibiotic. Antibiot Chemother 3:1283–1286
Chen DZ, Patel DV, Hackbarth CJ, Wang W, Drever G, Young DC, Margolis PS, Wu C, Ni CJ, Trias J, White RJ, Yuan Z (2000) Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochem 39:1256–1262
Citron DM, Goldstein JC (2011) Comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. In: 51st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, E-111
Coates T, Bax R, Coates A (2009) Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 64:9–15
Coates ARM, Halls G, Hu Y (2011) Novel classes of antibiotics or more of the same? Br J Pharmacol 163:184–194
Cooper A (1966) The crystal structure of fusidic acid methyl ester 3-p-bromobenzoate. Tetrahedron 22:1379–1381
Cordier C, Morton D, Murrison S, Nelson A, O’Leary-Steele C (2008) Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. Nat Prod Rep 25:719–737
Corey GR, Moellering R, Grayson ML (eds) (2011) Fusidic acid enters the United States. Clin Infect Dis 52(Suppl 7):S467–S546
Dang V, Nanda N, Cooper TW, Greenfield RA, Bronze MS (2007) Macrolides, azalides, ketolides, lincoamides, and streptogramins. J Okla State Med Assoc 100:75–81
Devasahayam G, Scheld WM, Hoffman PS (2010) Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 19:215–234
Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D (2010) Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot 63:423–430
Doublet B, Schwarz S, Kehrenberg C, Cloeckaert A (2005) Florfenicol resistance gene floR is part of a novel transposon. Antimicrob Agents Chemother 49:2106–2108
Dryden MS (2010) Complicated skin and soft tissue infection. J Antimicrob Chemother 65(Suppl 3):35–44
Dunkle JA, Xiong L, Mankin AS, Cate JHD (2010) Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc Nat Acad Sci USA 107:17152–17157
Ehrlich J, Bartz QR, Smith RM, Joslyn DA, Burkholder PR (1947) Chloromycetin, a new antibiotic from a soil actinomycete. Science 106:417
Falagas ME, Grammatikos AP, Michalopoulos A (2008) Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 6:593–600
Farrell DJ, Castanheira M, Chopra I (2011) Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52(Suppl 7):S487–S492
Fong IW, Drlica K (eds) (2008) Antimicrobial resistance and implications for the twenty-first century. Springer, New York
Frei CR, Miller ML, Lewis JS, Lawson KA, Peddaiahgari R, Talbert RL (2010) Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections. Clin Ther 32:2024–2029
Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, Cars O (2011) Critical shortage of new antibiotics in development against multi-resistant bacteria. Drug Resist Update 14:118–124
Fuller AT, Mellows G, Woolford M, Banks GT, Barrow KD, Chain EB (1971) Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature 234:416–417
Gao Y-G, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V (2009) The structure of the ribosome with elongation factor G trapped in the posttranslational state. Science 326:694–699
Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L (1962) Fusidic acid: a new antibiotic. Nature 193:987
Godtfredsen WO, von Daehne W, Vangedal S, Marquet A, Arigoni D, Melera A (1965) The stereochemistry of fusidic acid. Tetrahedron 21:3505–3530
Guay D (2007) Update on clindamycin in the management of bacterial, fungal and protozoal infections. Expert Opin Pharmacother 8:2401–2444
Gurel G, Blaha G, Moore PB, Steitz TA (2009) U2504 determines the species specificity of the A-site cleft antibiotics. J Mol Biol 389:146–156
Hansen JL, Moore PB, Steitz TA (2003) Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J Mol Biol 330:1061–1075
Harms JM, Schlunzen F, Fucini P, Bartels H, Yonath A (2004) Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramin dalfopristin and quinupristin. BMC Biol 2:4
Harms JM, Wilson DN, Schluenzen F, Connell SR, Stachelhaus T, Zaborowska Z, Spahn CM, Fucini P (2008) Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell 30:26–38
Hartley AJ, de Mattos-Shipley K, Collins CM, Kilaru S, Foster GD, Bailey AM (2009) Investigating pleuromutilin-producing Clitopilus species and related basidiomycetes. FEMS Microbiol Lett 297:24–30
Hensens OD, Albers-Schonberg G (1983) 13C NMR study of thiostrepton and thiopeptin components. J Antibiot 36:832–845
Hermann T (2005) Drugs targeting the ribosome. Curr Opin Struct Biol 15:355–366
Hothersall J, Wu J, Rahman AS, Shields JA, Haddock J, Johnson N, Cooper SM, Stephens ER, Cox RJ, Crosby J, Willis CL, Simpson TJ, Thomas CM (2007) Mutational analysis reveals that all tailoring region genes are required for production of polyketide antibiotic mupirocin by Pseudomonas fluorescens. J Biol Chem 282:15451–15461
Hu C, Zou Y (2009) Mutilins derivatives: from veterinary to human-used antibiotics. Mini-Rev Med Chem 9:1397–1406
Hughes RA, Moody CJ (2007) From amino acids to heteroaromatics—thiopeptide antibiotics, nature’s heterocyclic peptides. Angew Chem Int Ed 46:7930–7954
IDSA (2010) The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081–1083
Jacobs MR (2010) Retapamulin: focus on its use in the treatment of uncomplicated superficial skin infections and impetigo. Expert Rev Dermatol 5:505–513
Johnston NJ, Mukhtar TA, Wright GD (2002) Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets 3:335–344
Kannan K, Mankin AS (2011) Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann N Y Acad Sci 1241:33–47
Kanyo Z, Devivo M, Bhattacharjee A, Ippolito J, Wimberly B, Duffy E (2011) Structural basis for the binding of RX-04, a novel broad spectrum antibacterial class, to bacterial ribosomes. In 51st interscience conference on antimicrobial agents chemotherapy, Chicago, IL, F1-1842
Kavanagh F, Hervey A, Robbins WJ (1951) Antibiotic substances from Basidiomycetes. Proc Natl Acad Sci U S A 37:570–574
Khemawoot P, Saunders D, Rasameesoraj M, Melendez V, Imerbsin R, Ohrt C, Fracisco S, Teja-isavadharm P (2011) Absolute bioavailability of cis-mirincamycin and trans-mirincamycin in healthy rhesus monkeys and ex vivo antimalarial activity against Plasmodium falciparum. Antimicrob Agents Chemother 55:5881–5886
Kirst HA (ed) (2010a) Antibiotics versus resistant bacteria: a continual challenge. Expert Opin Ther Patents 20: 1271–1420
Kirst HA (2010b) New macrolide, lincosaminide and streptogramin B antibiotics. Expert Opin Ther Patents 20:1343–1357
Kirst HA (2012) Recent derivatives from smaller classes of fermentation-derived antibacterials. Expert Opin Ther Patents 22:15–35
Kluka EA (2011) Emerging dilemmas with methicillin-resistant Staphylococcus aureus infections in children. Curr Opin Otolaryngol Head Neck Surg 19:462–466
Korczynska M, Mukhtar TA, Wright GD, Berghuis AM (2007) Structural basis for streptogramin B resistance in Staphylococcus aureus by virginiamycin B lyase. Proc Natl Acad Sci U S A 104:10388–10393
Kumasaka T, Yamamoto M, Furuichi M, Nakasako M, Teh A-H, Kimura M, Yamaguchi I, Ueki T (2007) Crystal structures of blasticidin S deaminase (BSD). J Biol Chem 282:37103–37111
LaMarche MJ, Leeds JA, Dzink-Fox J, Gunderson K, Krastel P, Memmert K, Patane MA, Rann EM, Schmitt E, Tiamfook S, Wang B (2011) 4-Aminothiazolyl analogues of GE2270 A: antibacterial lead finding. J Med Chem 54:2517–2521
Lange RP, Locher HH, Wyss PC, Then RL (2007) The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des 13:3140–3154
Lechtenberg KF, Nagaraja TG, Chengappa MM (1998) Antimicrobial susceptibility of Fusobacterium necrophorum isolated from bovine hepatic abscesses. Am J Vet Res 59:44–47
Leclercq R, Courvalin P (1991) Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 35:1267–1272
Lee VJ (2007) Anti-Gram-positive agents of natural product origins. In: Triggle DJ, Taylor JB (eds) Comprehensive medicinal chemistry II, vol 7. Elsevier, Oxford
Leeds JA, LaMarche MJ, Brewer JT, Bushell SM, Deng G, Dewhurst JM et al (2011) In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu. Antimicrob Agents Chemother 55:5277–5283
Lentzen G, Klinck R, Matassova N, Aboul-ela F, Murchie AIH (2003) Structural basis for contrasting activities of ribosome binding thiazole antibiotics. Chem Biol 10:769–778
Lewis C (1974) Clinically useful antibiotics obtained by directed chemical modification—lincomycins. Fed Proc 33:2303–2306
Li C, Kelly WL (2010) Recent advances in thiopeptide antibiotic biosynthesis. Nat Prod Rep 27:153–164
Li C, Zhang F, Kelly WL (2011) Heterologous production of thiostrepton A and biosynthetic engineering of thiostrepton analogs. Mol BioSyst 7:82–90
Loncaric C, Wulff WD (2001) An efficient synthesis of (-)-chloramphenicol via asymmetric catalytic aziridination. Org Lett 3:3675–3678
Ma Z, Ginsberg AM, Spigelman M (2007) Antimycobacterium agents. In: Triggle DJ, Taylor JB (eds) Comprehensive medicinal chemistry II, vol 7. Elsevier, Oxford
Manfredi R (2005) A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant Gram-positive nosocomial cocci in hospital setting. Mini-Rev Med Chem 5:1075–1081
Marcinak JF, Frank AL (2006) Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children. Expert Opin Anti-Infect Ther 4:91–100
Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Duffy E (2011) Novel ribosome inhibitors are efficacious in a murine peritonitis model caused by different bacterial pathogens. In 51st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, F1-1854
Mason DJ, Dietz A, DeBoer C (1963) Lincomycin, a new antibiotic. In: Antimicrobial agents and chemotherapy 1962. Williams & Wilkins, Baltimore, pp 554–559
Maviglia R, Nestorini R, Pennisi MA (2009) Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets 10:895–905
McCoy LS, Xie Y, Tor Y (2011) Antibiotics that target protein synthesis. WIREs RNA 2:209–232
Mikolajka A, Liu H, Chen Y, Starosta AL, Marquez V, Ivanova M, Cooperman BS, Wilson DN (2011) Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases. Chem Biol 18:589–600
Mitscher LA (2010) Tetracycline, aminoglycoside, macrolide, and miscellaneous antibiotics. In: Abraham DJ, Rotella DP (eds) Burger’s medicinal chemistry, drug discovery, and development, 7th edn. Wiley, New York
Mlynarczyk B, Mlynarczyk A, Kmera-Muszynska M, Majewski S, Mlynarczyk G (2010) Mechanisms of resistance to antimicrobial drugs in pathogenic Gram-positive cocci. Mini-Rev Med Chem 10:928–937
Morar M, Bhullar K, Hughes DW, Junop M, Wright GD (2009) Structure and mechanism of the lincosamide antibiotic adenylyltransferase LinB. Structure 17:1649–1659
Muir LA, Rickes EL, Duquette PF, Smith GE (1981) Prevention of induced lactic acidosis in cattle by thiopeptin. J Anim Sci 52:635–643
Nailor MD, Sobel JD (2009) Antibiotics for Gram-positive infections. Infect Dis Clin N Am 23:965–982
Nicolaou KC, Zak M, Safina BS, Lee SH, Estrada AA (2004) Total synthesis of thiostrepton, Part 2. Construction of the quinaldic acid macrocycle and final stages of the synthesis. Angew Chem Int Ed 43:5092–5097
Nicolaou KC, Zak M, Rahimipour S, Estrada AA, Lee SH, O’Brate A, Giannakakou P, Ghadiri MR (2005) Discovery of a biologically active thiostrepton fragment. J Am Chem Soc 127:15042–15044
Novak R, Shlaes DM (2010) The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 11:182–191
Pagano JF, Weinstein MJ, Stout HA, Donovick R (1956) Thiostrepton, a new antibiotic. 1. In vitro studies. Antibiot Annu 1955–1956(3):554–559
Patel JB, Gorwitz RJ, Jernigan JA (2009) Mupirocin resistance. Clin Infect Dis 49:935–941
Pohlmann J, Brotz-Oesterhelt H (2004) New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disorders 4:261–272
Politano AD, Sawyer RG (2010) NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs 11:225–236
Poulsen SM, Karlsson M, Johansson LB, Vester B (2001) The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol Microbiol 41:1091–1099
Pulcini C et al (2012) Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 54:268–274
Rib-X Pharmaceuticals (2012) www.rib-x.com/research-discovery/publications-presentations.php#RX04
Roberts MC (1999) Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43:2823–2830
Roberts MC (2008) Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 282:147–159
Roberts MC (2011) Environmental macrolide-lincosamide-streptogramin and tetracycline resistant bacteria. Frontiers Microbiol 2:40–47
Saini V, Olde Riekerink RGM, McClure JT, Barkema HW (2011) Diagnostic accuracy assessment of sensititre and agar disk diffusion for determining antimicrobial resistance profiles of bovine clinical mastitis pathogens. J Clin Microbiol 49:1568–1577
Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F (2001) Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413:814–821
Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM (2004) Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 54:1287–1294
Schofer H, Simonsen L (2010) Fusidic acid in dermatology: an updated review. Eur J Dermatol 20:6–15
Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A (2004) Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28:519–542
Schwarz S, Kehrenberg C (2006) Old dogs that learn new tricks: modified antimicrobial agents that escape pre-existing resistance mechanisms. Int J Med Microbiol 296(Suppl 2):45–49
Sharma A, Khuller GK, Sharma S (2009) Peptide deformylase—a promising therapeutic target for tuberculosis and antibacterial drug discovery. Expert Opin Ther Targets 13:753–765
Sivapalasingam S, Steigbigel NH (2010) Macrolides, clindamycin, and ketolides. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 7th edn. Churchill Livingstone, Philadelphia
Sutcliffe JA (2011) Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241:122–152
Takeuchi S, Hirayama K, Ueda K, Yonehara H (1958) Blasticidin S, a new antibiotic. J Antibiot 11:1–5
Tang YZ, Liu YH, Chen JX (2012) Pleuromutilin and its derivatives—the lead compounds for novel antibiotics. Mini-Rev Med Chem 12:53–61
Tenson T, Lovmar M, Ehrenberg M (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 330:1005–1014
Thomas CM, Hothersall J, Willis CL, Simpson TJ (2010) Resistance to and synthesis of the antibiotic mupirocin. Nature Rev Microbiol 8:281–289
Tu D, Blaha G, Moore PB, Steitz TA (2005) Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121:257–270
Vondenhoff GHM, van Aerschot A (2011) Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 46:5227–5236
Weinberg JM, Tyring SK (2010) Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol 9:1198–1204
Weisblum B (1995) Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 39:577–585
White DG, Hudson C, Maurer JJ, Ayers S, Zhao S, Lee MD, Bolton L, Foley T, Sherwood J (2000) Characterization of chloramphenicol and florphenicol resistance in Escherichia coli associated with bovine diarrhea. J Clin Microbiol 38:4593–4598
Wilson DN (2011) On the specificity of antibiotics targeting the large ribosomal subunit. Ann N Y Acad Sci 1241:1–16
Yang K, Fang H, Gong J, Su L, Xu W (2009) An overview of highly optically pure chloramphenicol bases: applications and modifications. Mini-Rev Med Chem 9:1329–1341
Yonath A (2005) Antibiotics targeting ribosomes. Annu Rev Biochem 74:649–679
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kirst, H.A. (2014). Protein Synthesis Inhibitors from Smaller Antibiotic Classes. In: Marinelli, F., Genilloud, O. (eds) Antimicrobials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39968-8_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-39968-8_14
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39967-1
Online ISBN: 978-3-642-39968-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)